Shaw Julie L V, Grass Linda, Sotiropoulou Georgia, Diamandis Eleftherios P
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada, M5G 1X5.
Clin Biochem. 2007 Jan;40(1-2):104-10. doi: 10.1016/j.clinbiochem.2006.07.011. Epub 2006 Aug 25.
Human kallikrein 15 (KLK15) may have some utility as a prostate, ovarian, and breast cancer biomarker, based on previous studies, which examined mRNA levels of KLK15. The aim of this study was to develop analytical technology for human kallikrein 15, including recombinant protein, specific antibodies, and a sensitive and specific ELISA immunoassay. The assay was then used to examine levels of KLK15 in tissues and biological fluids.
We produced human, recombinant pro-KLK15 in HEK 293 cells. Recombinant KLK15 was purified with various chromatographic steps and used to immunize rabbits and mice for production of KLK15 polyclonal antibodies. We used these antibodies to develop a highly sensitive and specific KLK15 immunoassay and to study KLK15 expression in various tissues and biological fluids.
Large amounts of pure, recombinant KLK15 have been produced and characterized. KLK15 mouse and rabbit polyclonal antibodies have been employed for development of a KLK15 immunoassay. This assay has a lower detection limit of 0.05 microg/L, and no cross-reactivity with any of the other fourteen kallikreins. Using this assay, KLK15 was detected in prostate, colon, and thyroid tissues, as well as in breast milk and seminal plasma.
The KLK15 reagents developed here will allow for analysis of KLK15 protein expression levels in tissues and biological fluids, both normal and cancerous. This will expand upon previously characterized tissue KLK15 mRNA expression studies which suggested that KLK15 might be useful as a biomarker for breast, ovarian, and prostate cancer. KLK15 is another serine protease that is produced in prostate and other tissues and is secreted in seminal plasma and other fluids. Its physiological function needs to be further elucidated.
根据之前检测人激肽释放酶15(KLK15)mRNA水平的研究,KLK15可能作为前列腺癌、卵巢癌和乳腺癌的生物标志物。本研究的目的是开发针对人激肽释放酶15的分析技术,包括重组蛋白、特异性抗体以及灵敏且特异的ELISA免疫测定法。然后使用该测定法检测组织和生物体液中KLK15的水平。
我们在HEK 293细胞中生产人重组前激肽释放酶15。通过各种色谱步骤纯化重组KLK15,并用于免疫兔和小鼠以产生KLK15多克隆抗体。我们使用这些抗体开发了一种高度灵敏且特异的KLK15免疫测定法,并研究KLK15在各种组织和生物体液中的表达。
已生产并鉴定出大量纯的重组KLK15。KLK15小鼠和兔多克隆抗体已用于开发KLK15免疫测定法。该测定法的检测下限为0.05μg/L,并且与其他十四种激肽释放酶均无交叉反应。使用该测定法,在前列腺、结肠和甲状腺组织以及母乳和精浆中检测到了KLK15。
此处开发的KLK15试剂将能够分析正常和癌性组织及生物体液中KLK15蛋白的表达水平。这将扩展先前对组织KLK15 mRNA表达的研究,这些研究表明KLK15可能作为乳腺癌、卵巢癌和前列腺癌的生物标志物。KLK15是另一种在前列腺和其他组织中产生并分泌到精浆和其他体液中的丝氨酸蛋白酶。其生理功能有待进一步阐明。